Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial ifngammar2 deficiency is a rare genetic immune condition. It weakens the body’s ability to fight mycobacteria, so people may have recurrent or severe infections and fevers. Early symptoms of autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial ifngammar2 deficiency often start in childhood but can appear later. Most people live into adulthood, but complications from serious infections can be dangerous without prompt care. Treatment focuses on preventing and treating infections with antibiotics, sometimes antifungals, and specialist-guided immune therapies.
Overview
Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial ifngammar2 deficiencySymptoms
Early symptoms of Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial ifngammar2 deficiency are recurrent or unusually severe mycobacterial infections, often after BCG vaccination. Signs include prolonged fever, swollen lymph nodes, and skin, lung, bone, or bloodstream infections.
Outlook and prognosis
Most people with autosomal dominant Mendelian susceptibility to mycobacterial disease due to partial IFN-γR2 deficiency can stay well between infections, but they face higher risk from certain mycobacteria, including BCG and environmental species. With prompt antibiotics, tailored immunomodulatory care, and careful vaccine planning, many achieve good long‑term control. Outcomes are best when infections are recognized early and managed by an experienced immunology–infectious diseases team.
Causes and risk factors
Autosomal dominant mendelian susceptibility to mycobacterial diseases due to IFN‑gamma receptor 2 deficiency stems from an inherited or new IFNGR2 gene mutation. Risk factors for this condition include family history, BCG exposure, TB-endemic travel, malnutrition, and immune-weakening conditions.
Genetic influences
Genetics is central in Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFN-γR2 deficiency. A single altered copy of the IFN-γ receptor 2 gene reduces signaling, weakening defense against mycobacteria. Family history strongly affects risk; first‑degree relatives may carry the variant.
Diagnosis
Diagnosis relies on a history of invasive or recurrent mycobacterial infections and immune tests showing reduced interferon-gamma signaling. Genetic diagnosis of Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial ifngammar2 deficiency is confirmed by IFNGR2 sequencing.
Treatment and drugs
Treatment focuses on preventing and controlling infections. People with autosomal dominant Mendelian susceptibility to mycobacterial diseases due to partial IFN-γR2 deficiency often receive targeted antibiotics for nontuberculous mycobacteria, careful monitoring, and preventive antibiotics after exposures or procedures. Some benefit from interferon‑gamma therapy and prompt vaccination updates with non-live vaccines, guided by an immunology specialist.
Symptoms
People with Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial ifngammar2 deficiency tend to have an immune system that struggles to control certain mycobacterial germs. Early features of Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial ifngammar2 deficiency can include infections that are unusually frequent, long-lasting, or severe, especially after the BCG vaccine or from environmental exposure. Features vary from person to person and can change over time. Many first notice swollen glands, stubborn skin sores, or a cough that lingers during an infection.
Tender, enlarged glands (lymph nodes) in the neck, underarm, or groin can persist for weeks or months. They often follow a skin or vaccine site problem and may drain or feel warm.
Small cuts, injection sites, or random bumps can turn into firm, draining sores that are slow to heal. These often trace back to mycobacterial germs in the skin.
After the BCG vaccine, the injection site can become large, painful, or persistently draining, or nearby glands can swell. This can be an early clue to Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial ifngammar2 deficiency.
A cough that lingers for weeks, sometimes with chest discomfort or shortness of breath, can signal lung involvement. Chest infections may clear slowly or return after antibiotics.
How people usually first notice Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial ifngammar2 deficiency?
Families often first notice frequent, unusually severe infections from bugs that are usually mild, such as non-tuberculous mycobacteria after routine BCG vaccination or environmental exposures, or recurrent bacterial infections that don’t clear as expected. Doctors may see poor responses to standard antibiotics, persistent fevers, swollen lymph nodes, or unusual skin, bone, or lung infections, prompting immune workups that reveal the “first signs of Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFN-γR2 deficiency.” In many, how this condition is first noticed is during early childhood after a vaccine reaction or a stubborn infection triggers testing that shows impaired interferon-gamma signaling.
Types of Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial ifngammar2 deficiency
People living with autosomal dominant Mendelian susceptibility to mycobacterial diseases due to partial IFN-γ receptor 2 (IFNGR2) deficiency often share a core pattern: frequent, sometimes severe infections from weak mycobacteria (like BCG vaccine strains or environmental mycobacteria), and occasionally from other intracellular germs. Still, how often infections happen and how hard they hit can vary by the exact change in the IFNGR2 gene and how much signaling is left. Clinicians often describe them in these categories: partial versus complete receptor dysfunction, with partial forms generally milder but still potentially serious. Not everyone will experience every type, and the balance of symptoms can shift over time.
Partial IFNGR2
This variant leaves some interferon-gamma signaling intact, so infections may start later in childhood and be less frequent. People with this type often have milder but recurrent mycobacterial infections and may recover better with treatment. Flares can occur during stressors like illness or after live mycobacterial vaccines.
Complete IFNGR2
Signaling is essentially absent, leading to severe, early, and recurrent mycobacterial infections that can be life-threatening. Infections often begin in infancy, involve multiple organs, and are hard to control. Growth problems and serious complications are more common.
Dominant-negative
A faulty receptor subunit interferes with the normal one, reducing signaling even when one gene copy is healthy. People may have moderate to severe infections from BCG or environmental mycobacteria and sometimes from salmonella. Symptoms don’t always look the same for everyone.
Hypomorphic alleles
Changes that reduce but do not eliminate receptor function can present as partial IFN-γ signaling, with variable severity. Some have long infection-free periods, then clusters of mycobacterial illness, especially after exposures. These variants of autosomal dominant MSMD help explain why types of autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFN-γR2 deficiency can look different family to family.
What genetics can tell you about symptoms
Some people with partial IFN-γ receptor 2 (IFNGR2) changes develop repeated or severe infections from weak mycobacteria, like BCG vaccine strains or environmental mycobacteria. The gene change blunts immune signaling, so infections last longer, spread deeper, and may cause fever, lymph node swelling, or pneumonia.
Causes and risk factors
This condition is caused by a change in the IFN‑gamma receptor 2 gene that weakens the signal needed to control mycobacterial germs. Early symptoms of autosomal dominant Mendelian susceptibility to mycobacterial disease may appear after a BCG shot or after contact with tuberculosis. Having a gene change doesn’t mean you’ll definitely develop the condition. It can be inherited from a parent in an autosomal dominant way or arise as a new change. Risk also rises with high mycobacterial exposure, poor nutrition, young age, or medicines that lower immunity, but these factors modify severity rather than cause the disorder.
Environmental and biological risk factors
This condition, Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial ifngammar2 deficiency, begins before birth and relates to how immune signals are received. Doctors often group risks into internal (biological) and external (environmental). Below are environmental and biological factors that may influence how likely it is to arise in a child.
Fathers in their mid-40s or older have a higher chance of new, random changes arising in sperm. This slightly raises the chance of conditions that start before birth. The absolute risk remains low for any one pregnancy.
Pregnancy at age 35 or above is linked with more new changes during egg formation. This may modestly increase the chance of a condition that begins before birth. Most pregnancies at this age are healthy.
Very high ionizing radiation to a parent before conception (for example, certain cancer treatments or major accidents) can increase new changes in reproductive cells. This could rarely contribute to conditions present from birth. Routine diagnostic imaging uses far lower doses and is not linked to this risk.
Very high radiation exposure early in pregnancy can disrupt cell signaling during development. This could, in rare cases, create changes that lead to a condition present from birth. Medical teams use shielding and careful protocols to avoid this.
Genetic risk factors
This condition usually stems from a change in the IFN-gamma receptor 2 (IFNGR2) gene that weakens how immune cells respond to the IFN-gamma signal. In Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial ifngammar2 deficiency, a single altered copy can be enough to raise risk, though the receptor still works to a degree. Carrying a genetic change doesn’t guarantee the condition will appear. Understanding the genetic causes of autosomal dominant IFNGR2 deficiency can guide testing and family planning.
IFNGR2 gene changes: Disease-causing changes in IFNGR2 reduce the number or function of IFN-gamma receptor 2 on immune cells. This weakens the signal that normally helps the body control mycobacterial infections. The defect is partial, so some signaling remains.
Autosomal dominant pattern: One altered copy can increase risk, so each child has a 50% chance of inheriting it. The chance is the same for all sexes. Families may notice affected relatives across multiple generations.
Partial function preserved: The receptor still passes some signals even when altered. This “turned-down” response is enough to raise susceptibility but not to eliminate defense entirely. It helps explain why infections cluster around certain mycobacteria.
Incomplete penetrance: Not everyone who inherits the variant develops infections, and severity can differ widely. Age at first infection can range from early childhood to adulthood. Other inherited factors likely shape the final picture.
Family history: Having a parent or sibling with a confirmed IFNGR2 change increases your chance of carrying it. Clues in a family can include severe reactions to BCG vaccine or recurrent non-tuberculous mycobacterial infections. Genetic counseling can map the pattern and identify relatives to test.
De novo variants: Sometimes the IFNGR2 change appears for the first time in a child, with no prior family history. A parent may test negative in blood yet carry the change in a small fraction of cells (mosaicism). When mosaicism is present, recurrence risk is usually low but not zero.
Pathway mechanism: Variants can affect how the receptor is built, reaches the cell surface, or transmits the signal inside the cell. The result is a dampened IFN-gamma response rather than a complete shutdown. This selective effect aligns with the specific infection risks seen.
Genetic testing: Sequencing the IFNGR2 gene can confirm the diagnosis and clarify who in the family carries the change. Functional immune tests may be added to document partial signaling. Results can guide monitoring and early care for at-risk relatives.
Variant types: Single-letter changes in the gene or alterations that disrupt splicing are commonly reported. Small insertions or deletions can also cause partial IFNGR2 deficiency. Different changes can produce different degrees of signaling loss.
Lifestyle risk factors
This condition is genetic; lifestyle habits do not cause it, but they can influence infection risk, symptom control, and complications. Focusing on how lifestyle affects autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFN-gammaR2 deficiency can help reduce mycobacterial and other opportunistic infections and support recovery. The elements below highlight practical behaviors that directly impact immune resilience and infection burden in this condition.
Adequate protein and micronutrients support macrophage and T-cell function that help contain mycobacterial infections in partial IFN-gammaR2 deficiency. Skipping meals or low-protein diets can worsen fatigue and slow recovery during infections.
Maintaining sufficient vitamin D may bolster antimicrobial pathways (like cathelicidin) that aid control of mycobacteria despite partial IFN-gamma signaling. Deficiency has been linked to higher risk and severity of mycobacterial disease.
Regular moderate exercise can improve lung clearance and overall immune readiness, lowering respiratory mycobacterial infection risk. Very intense or prolonged training may transiently suppress immunity and increase susceptibility.
Consistent 7–9 hours of sleep helps maintain cytokine balance and pathogen-fighting cells that are especially needed when IFN-gamma signaling is partially impaired. Short or irregular sleep can increase infection frequency and prolong illness.
Risk prevention
Autosomal dominant Mendelian susceptibility to mycobacterial diseases due to partial IFN‑gamma receptor 2 deficiency is genetic, so you can’t fully prevent the condition itself. Prevention focuses on lowering the chance of serious infections and catching problems early so treatment starts quickly. Even if you can’t remove all risks, prevention can reduce their impact. Day to day, that means smart vaccine choices, avoiding high‑risk exposures, safe food and water practices, and a clear plan with your care team.
Work with an immunologist and infectious disease doctor to create a written plan for fevers, wounds, or new swollen lymph nodes. Agree in advance on when to seek care and which tests or antibiotics to start. Share the plan with your primary doctor and emergency teams.
People with this condition should not receive the BCG vaccine because it can cause severe infection. Make sure your vaccination record clearly notes this, especially for travel or newborn care.
Keep up with routine non‑live vaccines like flu and pneumococcal to reduce respiratory infections. Discuss live vaccines with your specialist on a case‑by‑case basis.
Limit time in crowded, poorly ventilated places in areas with higher tuberculosis rates, and use good ventilation or masks if exposure is likely. Screen promptly after any known contact with TB; screenings and check-ups are part of prevention too.
Transmission
Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFN‑gamma receptor 2 deficiency is a genetic condition, not something you can catch from someone else. If you’re wondering how Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFN‑gamma receptor 2 deficiency is inherited, it follows an autosomal dominant pattern: a parent with the gene change has a 50% chance of passing it to each child. Sometimes the gene change appears for the first time in a child (a new mutation), so there may be no prior family history. The infections people with this condition are prone to are caused by germs such as mycobacteria and may spread in the usual ways for those infections, but the underlying immune condition itself does not spread through contact.
When to test your genes
Consider genetic testing if you or close relatives have repeated, unusually severe infections from weak mycobacteria (like BCG or environmental mycobacteria) or severe disease after BCG vaccination. Testing also fits before biologic therapies that affect immunity, or when tailoring preventive antibiotics and vaccines. Seek counseling to interpret results and guide care.
Diagnosis
Frequent or unusually severe mycobacterial infections—sometimes after the BCG vaccine in infancy—often prompt testing for this rare immune problem. Doctors usually begin with your infection history and basic labs, then move to focused immune tests if the pattern fits. The genetic diagnosis of Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial ifngammar2 deficiency is typically confirmed by a combination of immune function studies and DNA testing.
Clinicians look for repeated or severe infections caused by mycobacteria, such as nontuberculous species or complications after BCG vaccination. This pattern raises suspicion that the interferon-gamma pathway is not working at full strength.
The exam focuses on swollen lymph nodes, persistent fevers, weight loss, or signs of lung, bone, or skin involvement. Imaging like chest X-ray or CT can show areas of infection or inflammation that support the clinical picture.
Cultures and molecular tests identify the exact mycobacterial species and check which medicines are likely to work. Confirming the germ helps separate routine infections from those seen in immune pathway conditions.
Functional blood tests check how white blood cells respond to interferon-gamma, a key defense signal. A reduced but not absent response fits a partial receptor problem rather than a complete block.
Stages of Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial ifngammar2 deficiency
Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial ifngammar2 deficiency does not have defined progression stages. The pattern depends on when and how someone is exposed to mycobacteria (for example, after BCG vaccination or from the environment) and how infections are treated, rather than a steady, predictable decline. Early symptoms of autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial ifngammar2 deficiency may include persistent fevers, swollen lymph nodes after BCG, or skin lesions that don’t heal as expected. Different tests may be suggested to help check how the immune system responds to interferon‑gamma, and diagnosis is usually confirmed with genetic testing of IFNGR2 alongside a review of past infections and lab results.
Outlook and prognosis
Living with autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFN-γR2 deficiency often means being well most of the time, but getting unusually severe or persistent infections from “weak” mycobacteria, like BCG after vaccination or environmental mycobacteria in soil and water. Many people ask, “What does this mean for my future?”, and the answer depends on how often infections occur, how quickly they’re recognized, and how well they respond to antibiotics. Doctors call this the prognosis—a medical word for likely outcomes. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle, including exposure risks and access to prompt care.
The outlook is generally more favorable than with complete IFN-γ receptor defects, because immune signaling is reduced but not fully absent. Early care can make a real difference, especially when clinicians consider this diagnosis and treat infections thoroughly. Severe infections can still happen, particularly with non-tuberculous mycobacteria; some people also get infections with salmonella or certain fungi. Mortality is possible during a disseminated infection, but with modern antibiotics, preventive strategies, and close follow-up, many people maintain good day-to-day health and normal life expectancy.
Looking at the long-term picture can be helpful. Preventing exposures where reasonable, seeking care quickly for persistent fevers, swollen lymph nodes, lingering cough, or weight loss, and discussing early symptoms of partial IFN-γ receptor deficiency with your team can reduce complications. Hematopoietic stem cell transplant is rarely considered in partial forms and is usually reserved for severe, recurrent, or life-threatening disease that doesn’t respond to medical therapy. Talk with your doctor about what your personal outlook might look like, including whether antibiotic prophylaxis, targeted vaccines, or specialist follow-up could lower your risk over time.
Long-term effects
People living with this condition often face repeat infections that come and go, with stretches of normal health between them. Long-term effects vary widely, depending on which germs are involved and how early infections are recognized. For autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFN-gammaR2 deficiency, the immune gap mainly shows up when the body meets certain mycobacteria. Over time, daily routines may revolve around recovering from infections and healing from the tissue damage they leave behind.
Episodes often involve environmental mycobacteria or the BCG vaccine strain, and can come back over the years. Illnesses may affect the skin, lungs, lymph nodes, or spread more widely.
In some, infection spreads beyond one area to the liver, spleen, or bone marrow and can become life-threatening. This risk is higher when the first exposure is in early infancy, such as after BCG vaccination.
Repeated lung or lymph node infections can leave lasting airway damage and scarring. Some may notice a long-term cough, breathlessness, or more frequent chest infections.
Ongoing or repeat infections can inflame bones (osteomyelitis) and cause persistent, draining lymph nodes. These may heal with scarring that can be tender or limit movement nearby.
How is it to live with Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial ifngammar2 deficiency?
Living with autosomal dominant Mendelian susceptibility to mycobacterial disease due to partial IFN-γR2 deficiency often means being generally well day to day, but facing a higher risk of serious infections from “weaker” mycobacteria (like BCG after vaccination or environmental nontuberculous mycobacteria) and sometimes other intracellular germs. For many, this leads to extra vigilance with vaccines and infections, more frequent check-ins with specialists, and prompt antibiotics if fevers or swollen lymph nodes appear, which can feel like carrying a quiet responsibility. Families and close friends often become partners in care—helping notice early signs, supporting adherence to treatment plans, and organizing safer travel or activities—while learning that with good prevention and rapid treatment, most routines, schooling, and work can continue. The emotional load eases when there’s a clear action plan and a medical team that knows the condition well.
Treatment and drugs
Treatment for autosomal dominant Mendelian susceptibility to mycobacterial diseases due to partial IFN-γ receptor 2 deficiency focuses on preventing and aggressively treating infections, especially from nontuberculous mycobacteria and certain live vaccines. Daily or long-term antibiotics (such as macrolides or rifamycins, sometimes in combination) are commonly used to control active infections and may be continued as suppression to prevent relapses; doctors also treat complications like abscesses with drainage when needed. Because the immune pathway that responds to interferon-gamma is partially blocked, injectable interferon-gamma is generally not useful in this condition, while prompt, targeted antimicrobials and careful monitoring are key. People with this condition should avoid live mycobacterial vaccines (for example, BCG), stay up to date with inactivated vaccines, and be managed by an infectious disease and immunology team that can adjust therapy during flares or exposures. Supportive care can make a real difference in how you feel day to day, including good skin and wound care, nutrition, and swift evaluation of new fevers, cough, swollen lymph nodes, or skin lesions.
Non-drug treatment
Living with frequent or severe mycobacterial infections can affect daily routines—from how you prepare food and water to how quickly you seek care for fevers or new cough. Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial ifngammar2 deficiency often benefits from a practical prevention plan and clear steps for when symptoms flare. Alongside medicines, non-drug therapies can strengthen day-to-day health, reduce infection risks, and support recovery. The goal is to lower exposures, catch problems early, and keep strength up between infections.
Wash hands often and use alcohol-based sanitizer when soap and water aren’t available. Wear a mask in crowded indoor spaces during outbreaks or when you’re recovering. Avoid untreated water, poorly chlorinated pools, and hot tubs where germs can linger.
Keep inactivated vaccines up to date for you and close contacts to create a protective “cocoon.” Avoid live vaccines, including BCG, unless your specialist advises otherwise. Ask your care team to review vaccine timing around any illness or procedures.
Limit direct contact with soil aerosols, unpasteurized dairy, and raw or undercooked meats. Use gloves for gardening and cover any cuts promptly. During travel, choose safe drinking water (bottled or boiled) and avoid high-risk water activities.
Learn the early symptoms of Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial ifngammar2 deficiency, such as persistent fever, swollen lymph nodes, new cough, or skin lesions. Keep a written action plan with who to call and where to go for urgent assessment. Seek care early to prevent complications.
Your genes may have an impact on how drugs work for you
For many living with autosomal dominant MSMD due to partial IFN-γR2 deficiency, genes can change how well antimycobacterial drugs and interferon-based therapies work. Variants may alter drug metabolism and immune signaling, so clinicians often individualize treatment and dosing.
Pharmacological treatments
Treatment centers on multidrug therapy to clear mycobacteria, with long courses tailored to the species and how sick someone is. While early symptoms of autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFN-γR2 deficiency usually come from the infection itself, medicines focus on clearing the mycobacteria and preventing new infections. Not everyone responds to the same medication in the same way. Interferon-gamma shots are usually not helpful here because the cell receptor is partly blocked, so other drug combinations and prevention strategies take the lead.
Most people start with a combination such as a macrolide (azithromycin or clarithromycin) plus a rifamycin (rifampin or rifabutin) and ethambutol. Severe disease may add isoniazid or an injectable like amikacin for a period. Ask your doctor why a specific drug was recommended for you.
Azithromycin or clarithromycin help suppress nontuberculous mycobacteria. They can cause stomach upset or taste changes and, rarely, affect heart rhythm, so ECG checks may be needed if you have risk factors.
Rifampin or rifabutin are backbone drugs for many mycobacterial infections. They interact with many medicines (for example, some HIV drugs and birth control), and can discolor urine and tears orange.
Ethambutol helps prevent resistance when used with other drugs. Vision and color perception should be monitored during treatment, and doses are adjusted if kidney function is reduced.
Genetic influences
In this condition, one altered copy of a key immune-system gene is enough to raise risk, so it follows an autosomal dominant pattern—each child of an affected parent has a 50% chance of inheriting it. A change in a gene (mutation or variant) can sometimes affect health. The gene involved, called interferon‑gamma receptor 2 (IFNGR2), helps immune cells respond to an infection‑fighting signal; with a partial deficiency, that signal is turned down, which makes it harder to control certain mycobacterial germs such as BCG from vaccines or environmental nontuberculous mycobacteria. Because function is reduced rather than completely absent, severity can vary within the same family—some relatives have frequent or more serious infections, while others have few problems until a particular exposure. The gene change can be inherited from an affected parent or, less commonly, arise for the first time in a child, so a clear family history may or may not be present. Genetic testing of IFNGR2 can confirm Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial ifngammar2 deficiency and guide testing of relatives, family planning, and expectations around early symptoms of Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial ifngammar2 deficiency.
Is Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial ifngammar2 deficiency genetic?
Genetics is central in Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFN-γR2 deficiency. A single altered copy of the IFN-γ receptor 2 gene reduces signaling, weakening defense against mycobacteria. Family history strongly affects risk; first‑degree relatives may carry the variant.
Pharmacogenetics—how genetics influence drug effects
Because the underlying issue is a partially working interferon‑gamma receptor, adding interferon‑gamma as a medicine often provides limited benefit, so care usually centers on targeted antibiotics and infection prevention. Genetic testing can sometimes identify how your body processes certain tuberculosis and nontuberculous mycobacterial medicines, which helps doctors choose safer doses or alternatives. One well‑studied example is isoniazid: people with slower activity of a common enzyme (NAT2) clear it more slowly and face a higher risk of side effects, so pharmacogenetic testing for isoniazid dosing may be considered when long courses are planned. Another is the risk of permanent hearing loss from aminoglycosides such as amikacin or streptomycin, which is much higher in those with a specific mitochondrial DNA change; some teams check for this before starting therapy. In Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial ifngammar2 deficiency, these drug–gene considerations are combined with close monitoring and culture results to tailor multi‑drug therapy. Other things still shape treatment—your liver health, age, other medicines, and the exact mycobacterial species—so genetics guides the plan but doesn’t replace clinical judgment.
Interactions with other conditions
People with Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFN‑gamma receptor 2 deficiency often run into more trouble when another immune‑weakening issue is present, such as HIV, poorly controlled diabetes, severe malnutrition, or long‑term steroid or anti‑TNF treatment. A condition may “exacerbate” (make worse) symptoms of another, so these added factors can turn usually mild germs—like the BCG vaccine strain or nontuberculous mycobacteria—into serious infections or make tuberculosis harder to control. This condition can also overlap with infections like Salmonella, which tend to be more frequent or severe because the same immune pathway is involved in fighting these bacteria. Live mycobacterial vaccines (like BCG) can trigger widespread infection, so vaccine plans need careful review, especially if travel or work increases exposure to mycobacteria. Chronic lung problems or structural airway changes can further raise the risk of nontuberculous mycobacterial disease, and coexisting liver or kidney disease may limit which antibiotics are safe. Talk with your doctor about how your conditions may influence each other, including whether any immune‑suppressing medicines or upcoming vaccines should be adjusted to lower infection risk and keep treatment effective.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described children who seemed healthy yet became very ill after routine infections or certain vaccines. Families sometimes recalled a cousin who recovered slowly from a “chest illness” or a sibling who struggled with swollen lymph nodes after a tuberculosis exposure. These patterns stood out because everyday colds passed uneventfully, but contact with mycobacteria—germs in the same broad family as tuberculosis—led to unusually severe disease.
First described in the medical literature as a rare problem of “selective vulnerability” to mycobacteria, the condition was initially recognized through clusters in families and unusually severe reactions to Bacille Calmette-Guérin (BCG) vaccination. Doctors noted that many living with these infections had otherwise normal growth and health. Over time, careful case reports showed that this susceptibility could run in families and follow a predictable inheritance pattern.
Building on this early work, scientists began to test how immune cells respond to interferon-gamma, a key immune messenger that helps the body contain mycobacteria. In the 1990s and early 2000s, research teams linked severe mycobacterial infections in children to problems in the interferon-gamma pathway. Some families had a complete loss of signaling and very severe disease; others had a partial signaling problem, leading to illness that ranged from mild to life-threatening depending on the exposure. This helped explain why one child might become very sick after BCG while a sibling had fewer complications.
Advances in genetics then identified changes in the interferon-gamma receptor—specifically the interferon-gamma receptor 2 (IFN-γR2)—as one cause. When this receptor works only partly, immune cells receive a weaker “go” signal. That partial deficit can be enough to tip the balance when facing mycobacteria. Once considered rare, now recognized as part of a broader group called Mendelian susceptibility to mycobacterial disease, this diagnosis brought together scattered reports under one umbrella and clarified why the spectrum of illness varies.
From early theories to modern research, the story of autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFN-γR2 deficiency shows how bedside observations and lab science inform each other. As genetic testing became more available, clinicians could confirm the diagnosis, offer family counseling, and tailor care. Not every early description was complete, yet together they built the foundation of today’s knowledge.
In recent decades, awareness has grown that early symptoms of this condition can be subtle until a meaningful exposure occurs. This shift has changed practice: doctors who see severe or unusual mycobacterial infections—especially after BCG or environmental nontuberculous mycobacteria—now consider testing the interferon-gamma pathway. Looking back helps explain why timely recognition and preventive steps matter today, and why families with a history of severe mycobacterial illness are offered genetic evaluation and guidance.